바로가기메뉴

본문 바로가기 주메뉴 바로가기

The Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2016, v.79 no.4, pp.274-281



  • Downloaded
  • Viewed

Abstract

Background: Factors associated with the prognosis of patients with small cell lung cancer (SCLC) is relatively unknown, than of those with non-small cell lung cancer. This study was undertaken to identify the prognostic factors of SCLC. Methods: The medical records of 333 patients diagnosed with SCLC at tertiary hospital from January 1, 2008, to December 31, 2012 were retrospectively reviewed. Patients were categorized by age (≤65 years vs. >65 years) and by extent of disease (limited disease [LD] vs extensive disease [ED]). Overall survival and progression free survival rates were determined. Factors associated with prognosis were calculated using Cox’s proportional hazard regression model. Results: Most baseline characteristics were similar in the LD and ED groups. Eastern Cooperative Oncology Group (ECOG) performance status (PS), first chemotherapy regimen, and prophylactic cranial irradiation (PCI) differed significantly in patients with LD and ED. Mean ECOG PS was significantly lower (p<0.001), first-line chemotherapy with etoposide-cisplatin was more frequent than with etoposide-carboplatin (p<0.001), and PCI was performed more frequently (p=0.019) in LD-SCLC than in ED-SCLC. Prognosis in the LD group was better in younger (≤65 years) than in older (>65 years) patients, but prognosis in the ED group was unrelated to age. Conclusion: This study showed that overall survival (OS) was significantly improved in younger than in older patients with LD-SCLC. Univariate and multivariate analyses showed that age, PCI and the sum of cycles were significant predictors of OS in patients with LD-SCLC. However, prognosis in the ED group was unrelated to age.

keywords
Prognosis, Small Cell lung Carcinoma, Age Groups

Reference

1.

1. Martini B. Lung cancer: epidemiology, prognosis and therapy. Med Monatsschr Pharm 2006;29:217-21.

2.

2. Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. Clin Lung Cancer 2015;16:282-91.

3.

3. Shin SY, Lyu Y, Shin Y, Choi HJ, Park J, Kim WS, et al. Lessons learned from development of de-identification system forbiomedical research in a Korean tertiary hospital. Healthc Inform Res 2013;19:102-9.

4.

4. Shin SY, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, et al. A Deidentification method for bilingual clinical texts of various note types. J Korean Med Sci 2015;30:7-15.

5.

5. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996;14:821-8.

6.

6. Gridelli C, Casaluce F, Sgambato A, Monaco F, Guida C. Treat-ment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question. Transl Lung Cancer Res 2016;5:150-4.

7.

7. Rossi A, Maione P, Colantuoni G, Guerriero C, Ferrara C, Del Gaizo F, et al. Treatment of small cell lung cancer in the elderly. Oncologist 2005;10:399-411.

8.

8. Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 2003;55:1321-30.

9.

9. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2010;67:221-6.

10.

10. Radzikowska E, Roszkowski K, Glaz P. Lung cancer in patients under 50 years old. Lung Cancer 2001;33:203-11.

11.

11. Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994;42:64-70.

Tuberculosis & Respiratory Diseases